Compare UA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | HROW |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | UA | HROW |
|---|---|---|
| Price | $5.95 | $34.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $71.14 |
| AVG Volume (30 Days) | ★ 2.5M | 953.3K |
| Earning Date | 02-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.90 |
| Revenue Next Year | $1.72 | $48.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $20.85 |
| 52 Week High | $7.91 | $54.98 |
| Indicator | UA | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 30.04 |
| Support Level | $5.88 | $30.55 |
| Resistance Level | $6.44 | $40.64 |
| Average True Range (ATR) | 0.27 | 2.21 |
| MACD | -0.13 | -0.67 |
| Stochastic Oscillator | 11.87 | 3.81 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.